INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ... leader in diabetes care since 1923, when we introduced ...

SAN FRANCISCO—Back in November, news of a cardiovascular outcomes win for Trulicity ... form—is also part of the group, and it showed in 2016 that it could cut cardiovascular problems by 26% ...

(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people ...

The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular ... risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings ...

20, 2019 /PRNewswire/ -- Eli Lilly and Company ... to assess the effect of Trulicity 1.5 mg, a weekly GLP-1 RA, compared to placebo, both added to standard of care (according to local standard ...

Lilly began its HCP marketing push for Trulicity last year, first targeting endocrinologists in November and then primary care providers in February. The drugmaker spent $5.49 million on professional ...